Travere Therapeutics, Inc. (TVTX)
Develops medicines for rare kidney and metabolic diseases.
$55.07-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+252.3%
The outlook
TVTX is trading near the top of its 52-week range with strong analyst support—the consensus rates it a Strong Buy, and the average price target sits about 7% above the current level. The stock is holding above both its 50- and 200-day moving averages, reflecting a solid uptrend in recent months.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 14 analysts
Price trendAbove its 50- & 200-day averages
52-week range89% of the way from its 52-week low to high
Price targetAvg target +7% vs current price
Analyst price target
~12-month · 14 analysts$58.71average target+6.6% vs now
Now $55.07
Low $43.00High $70.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$5.12B
52-wk high
$60.10
52-wk low
$15.03
50-day avg
$52.26
200-day avg
$37.90
Trailing P/E
—